Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 (the “2030 Convertible Notes”) will be 5,347.5936 shares of t.

businesswire.com - 2026-07-01 09:00:00

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the final tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 202.

businesswire.com - 2026-06-17 08:00:00

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 202.

businesswire.com - 2026-06-03 08:00:00

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has extended the early tender date (as extended, the “Extended Early Tender Date”) until 5:00 p.m., New York City time, on June 2, 2026 with respect to.

businesswire.com - 2026-06-02 08:00:00

[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (“Gossamer” or the â

gurufocus.com - 2026-06-01 13:00:00

NEW YORK--(BUSINESS WIRE)---- $GOSS #Bio--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has.

businesswire.com - 2026-06-01 12:38:00

New York, New York--(Newsfile Corp. - June 1, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law

feeds.newsfilecorp.com - 2026-06-01 12:00:00

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026, both dates inclusive (the “Class Period”).

globenewswire.com - 2026-06-01 12:00:00

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gos

gurufocus.com - 2026-06-01 10:00:00

LOS ANGELES--(BUSINESS WIRE)---- $GOSS--GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

businesswire.com - 2026-06-01 09:30:00

LOS ANGELES, June 01, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

globenewswire.com - 2026-06-01 09:27:00

GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

gurufocus.com - 2026-06-01 06:00:00

SAN FRANCISCO, June 1, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026. The lawsuit follows Gossamer's bombshell announcement on February 23, 2026 that top-line results for its Phase 3 PROSERA study did not meet the primary endpoint (the change from baseline in six-minute-walk distance at week 24).

prnewswire.com - 2026-06-01 05:28:00

Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GOSS PR Newswire

gurufocus.com - 2026-06-01 04:00:00

LOS ANGELES, June 1, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of GOSS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

prnewswire.com - 2026-06-01 03:50:00

LOS ANGELES, May 31, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

globenewswire.com - 2026-05-31 18:59:27

LOS ANGELES, May 31, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before June 1, 2026.

globenewswire.com - 2026-05-31 18:59:00

SAN FRANCISCO, May 31, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026.

globenewswire.com - 2026-05-31 17:43:06

SAN FRANCISCO, May 31, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026. The lawsuit follows Gossamer's bombshell announcement on February 23, 2026 that top-line results for its Phase 3 PROSERA study did not meet the primary endpoint (the change from baseline in six-minute-walk distance at week 24).

globenewswire.com - 2026-05-31 17:43:00

New York, New York--(Newsfile Corp. - May 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), of the important June 1, 2026 lead plaintiff deadline. SO WHAT: If you purchased Gossamer securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-05-31 12:04:00

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 31, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

newsfilecorp.com - 2026-05-31 08:50:00

NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), of the important June 1, 2026 lead plaintiff deadline.

globenewswire.com - 2026-05-30 18:52:00

NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”), of the important June 1, 2026 lead plaintiff deadline.

globenewswire.com - 2026-05-30 18:52:00

New York, New York--(Newsfile Corp. - May 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), of the important June 1, 2026 lead plaintiff deadline. SO WHAT: If you purchased Gossamer securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-05-30 11:17:00

GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Ri

gurufocus.com - 2026-05-30 10:00:00

SAN FRANCISCO, May 30, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026. The lawsuit follows Gossamer's bombshell announcement on February 23, 2026 that top-line results for its Phase 3 PROSERA study did not meet the primary endpoint (the change from baseline in six-minute-walk distance at week 24).

prnewswire.com - 2026-05-30 09:57:00

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 30, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

newsfilecorp.com - 2026-05-30 08:10:00

SAN FRANCISCO, May 29, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026. The lawsuit follows Gossamer's bombshell announcement on February 23, 2026 that top-line results for its Phase 3 PROSERA study did not meet the primary endpoint (the change from baseline in six-minute-walk distance at week 24).

globenewswire.com - 2026-05-29 14:48:00

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Gossamer (GOSS) To Contact Him Directly To Discuss Their Options

globenewswire.com - 2026-05-29 12:52:00

[url="]The Law Offices of Frank R. Cruz[/url] reminds investors of the upcoming June 1, 2026 deadline to participate as a lead plaintiff in the securities frau

gurufocus.com - 2026-05-29 12:00:00

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 1, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON GOSSAMER BIO, INC. (GOSS), CLICK HERE TO PARTICIPATE IN THE SECUR.

businesswire.com - 2026-05-29 12:00:00

New York, New York--(Newsfile Corp. - May 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), of the important June 1, 2026 lead plaintiff deadline. SO WHAT: If you purchased Gossamer securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-05-29 11:47:00

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 29, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

prnewswire.com - 2026-05-29 09:35:00

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS). Shareholders who purchased shares of GOSS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

globenewswire.com - 2026-05-29 09:00:00

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 28, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

newsfilecorp.com - 2026-05-28 19:23:00

NEW YORK, May 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), of the important June 1, 2026 lead plaintiff deadline. So What: If you purchased Gossamer securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

prnewswire.com - 2026-05-28 19:10:00

BENSALEM, Pa., May 28, 2026 /PRNewswire/ -- The Law Offices of Howard G.

prnewswire.com - 2026-05-28 15:28:00

New York, New York--(Newsfile Corp. - May 28, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026, both dates inclusive (the "Class Period").

newsfilecorp.com - 2026-05-28 12:00:00

LOS ANGELES, May 28, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before June 1, 2026.

globenewswire.com - 2026-05-28 10:05:00

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

prnewswire.com - 2026-05-28 10:00:00

SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026. The lawsuit follows Gossamer's bombshell announcement on February 23, 2026 that top-line results for its Phase 3 PROSERA study did not meet the primary endpoint (the change from baseline in six-minute-walk distance at week 24).

prnewswire.com - 2026-05-28 09:00:00

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”), of the important June 1, 2026 lead plaintiff deadline.

globenewswire.com - 2026-05-27 20:15:00

SAN FRANCISCO, May 27, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026.

globenewswire.com - 2026-05-27 19:54:49

SAN FRANCISCO, May 27, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026. The lawsuit follows Gossamer's bombshell announcement on February 23, 2026 that top-line results for its Phase 3 PROSERA study did not meet the primary endpoint (the change from baseline in six-minute-walk distance at week 24).

globenewswire.com - 2026-05-27 19:54:00

LOS ANGELES, May 27, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

globenewswire.com - 2026-05-27 12:07:00

LOS ANGELES, May 27, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). IF YOU SUFFERED A LOSS ON YOUR GOSSAMER INVESTMENTS, CLICK  HERE  BEFORE JUNE 1, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?

prnewswire.com - 2026-05-27 12:00:00

Philadelphia, Pennsylvania--(Newsfile Corp. - May 27, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Gossamer securities during the Class Period may, no later than June 1, 2026, seek to be appointed as a lead plaintiff representative of the class.

newsfilecorp.com - 2026-05-27 09:11:00

ATLANTA, May 27, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Gossamer Bio, Inc. (“Gossamer Bio” or the “Company”) (NASDAQ: GOSS). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Gossamer Bio's study design for its Phase 3 PROSERA study, particularly with respect to controlling for the placebo response at the Latin American testing sites.

globenewswire.com - 2026-05-27 08:00:00

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire

gurufocus.com - 2026-05-27 04:00:00

LOS ANGELES, May 27, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before June 1, 2026.

prnewswire.com - 2026-05-27 03:42:00